Embolization Procedures (Miscellaneous Vascular) Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity, prior authorization expectations, and coverage stance for various vascular embolization procedures for Medicare Advantage and Commercial members of Blue Cross Blue Shield - Rhode Island.
No material clinical or coverage changes in this revision.
Coverage Criteria for Vascular Embolization
inv-01: Medically Necessary Indications
Covered when ALL of the following medical criteria are met for the listed indications
List corresponds to items 1–18 in the policy medical criteria
inv-02: Lower Gastrointestinal Bleeding — Specific Criteria
Specific criteria for lower gastrointestinal bleeding embolization
Refers to policy item 11(a)–(c) and literature defining massive lower GI bleeding as ≥4 units/24 hours; super-selective embolization feasible in ~98% with 4.6% complication rate
inv-03: Renal angiomyolipoma (rAML) — Covered when supported by clinical indications and evidence
Covered when supported by clinical indications and evidence:
AML > 6 cm cited as imaging feature associated with higher bleeding risk (Torres and Pei 2024).
inv-04: Lower gastrointestinal bleeding — Covered when supported by clinical indications and severity
Covered when supported by clinical indications and severity:
Agents include coils, gelatin sponge, particles, glue; super-selective approach feasible in ~98% with ~4.6% complication rate.
inv-05: Portal vein embolization before hepatic resection — Covered when used as preoperative adjunct in select patients
Covered when used as preoperative adjunct in select patients:
Approximately 70–80% of patients who undergo PVE proceed to successful liver resection.
inv-06: Tumor-related and renal artery embolization — Covered when used to reduce operative risk or as accepted alternative
Covered when used to reduce operative risk or as accepted alternative:
NCCN guidelines support serial arterial embolizations for certain giant cell tumors; evidence supports use to reduce intraoperative bleeding.
inv-07: Prostatic arterial embolization (PAE) — Covered in specific refractory contexts
Covered in specific refractory contexts:
Tian et al (2019) concluded PAE is safe and effective in this context; available studies limited but evidence sufficient to determine effects on health outcomes for this indication.
inv-08: Evidence summaries and coverage stance by indication
Summary of evidence-based stance by indication:
Weiss 2019; less robust weight loss compared with surgical therapies.
Ironside et al 2021; meta-analysis of 20 studies, 1,416 patients.
Texakalidis et al 2019; 25 studies, 1,326 patients.
Insausti et al 2020; Abt et al 2018 referenced.
De Gregorio et al 2023.
This policy excludesPrior Authorization via Web‑Based Tool for Procedures and related prior authorization processes. Because embolization CPT codes are not body‑region specific, documentation and prior authorization workflows must clearly identify the targeted organ/procedure and clinical indication to ensure the correct authorization pathway is used.
The policy identifies multiple applications for which the available evidence is insufficient to determine effects on health outcomes. Examples include preventive collateral arteries embolization before EVAR to reduce type II endoleaks, locoregional embolization for metastatic pancreatic cancer outside clinical trials, embolization for persistent sciatic artery, paraumbilical vein coil embolization for hepatic encephalopathy, endovascular embolization for spinal dural arteriovenous fistula (SDAVF) where microsurgery may have superior outcomes, genicular artery embolization for osteoarthritis, HydroPearl microspheres for lower‑extremity AVMs or hemorrhoidal embolization, bariatric arterial embolization for obesity, and middle meningeal artery embolization for chronic subdural hematoma. These indications are characterized as investigational or requiring higher‑quality evidence before routine coverage.
The document does not present blanket categorical exclusions for many emerging procedures; rather, it repeatedly describes several indications as having insufficient evidence. Bariatric arterial embolization, middle meningeal artery embolization, pre‑operative carotid body tumor embolization, prostatic arterial embolization, and hemorrhoidal embolization are among the procedures noted as promising but lacking definitive evidence of net clinical benefit, and therefore are discussed as insufficient rather than explicitly excluded.
The policy lists specific procedures considered not covered / not medically necessary for Medicare Advantage Plans and Commercial Products because evidence is insufficient. These include coil embolization for left ventricular outflow tract (LVOT) pseudoaneurysm; locoregional embolization for metastatic pancreatic cancer (outside clinical trials); embolization for asymptomatic persistent sciatic artery; endovascular embolization for spinal dural arteriovenous fistula (when microsurgery demonstrates better outcomes); genicular artery embolization for osteoarthritis knee pain; hemorrhoidal embolization using HydroPearl microspheres; HydroPearl microspheres for lower‑extremity AVMs; bariatric arterial embolization to treat obesity; and prostatic arterial embolization for benign prostatic hyperplasia.
Procedures explicitly called out in the policy as lacking sufficient evidence include locoregional embolization for metastatic pancreatic cancer (recommended only in trial settings), paraumbilical vein coil embolization for hepatic encephalopathy, endovascular embolization for SDAVF when surgical outcomes are superior, genicular artery embolization pending higher‑quality trials, HydroPearl microspheres for lower‑extremity AVMs, and bariatric arterial embolization for obesity. The policy states that these interventions should not be provided outside research or selected cases with robust supporting documentation.
Emerging indications are discussed as promising but not yet established. Examples highlighted include bariatric arterial embolization for weight loss, middle meningeal artery embolization for chronic subdural hematoma, pre‑operative embolization for carotid body tumor resection, prostatic arterial embolization (PAE) for BPH‑related symptoms, and hemorrhoidal embolization. For each, the policy summarizes encouraging preliminary data but concludes the evidence is insufficient to determine net health outcome benefit and calls for additional high‑quality prospective trials.
Coding and Procedural Codes
| No codes listed |
| 37242 | Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (eg, congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms) |
| 37243 | Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction |
Provider Actions, Prior Authorization, and Documentation
Prior authorization requirement
Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products via the web‑based tool for participating providers.
Prior authorization for major indications
Prior authorization is appropriate when embolization is planned for major indications requiring demonstration of severity (for example, massive lower GI bleeding defined as transfusion ≥4 units in 24 hours, or PVE when a marginal future liver remnant is present and resection is contemplated).
Other provider actions
No additional provider actions are specified in this policy beyond the listed prior authorization, documentation, and benefit verification expectations.
Document prior/conservative therapy trials
Where applicable, document failure of or ineligibility for less‑invasive or medical therapies before embolization (for example, vasopressin infusion for GI bleeding or ≥3 months of medical management for BPH‑related hematuria prior to PAE).
- Record specific conservative treatments attempted and reasons for failure or ineligibility
- Include duration of medical management when required (e.g., ≥3 months for PAE)
Documentation clarity for embolization CPT codes
Because embolization CPT codes are not specific to a body region, documentation must state the specific procedure performed, the clinical indication, and supporting clinical details to allow medical necessity determination.
- Specify the embolization target (e.g., vessel and lesion)
- State the indication (e.g., active lower GI bleeding, renal AML hemorrhage, PVE for marginal FLR)
Suggested clinical documentation
Include clinical presentation, imaging results, prior conservative management, transfusion requirements when applicable, and rationale for choosing embolization over surgical alternatives.
- Clinical presentation: hemodynamic status, active bleeding, symptoms (e.g., flank pain, gross hematuria)
- Imaging: CT/MRI findings for hemorrhage or FLR assessment, angiographic localization
- Interventions/trials: prior endoscopy/colonoscopy, vasopressin infusion, medical therapy and durations
- Transfusion data: units transfused in 24 hours for GI bleeding
Benefit verification
Confirm benefits and eligibility per the member's subscriber agreement or employer agreement and follow participation agreement provisions for billing and member notification.
- Contact provider call center for member‑specific benefits
- Obtain written member agreement before billing for services determined non‑covered or not medically necessary
Denial-risk: not covered / not medically necessary procedures
Procedures identified in the policy as not covered or not medically necessary (examples include genicular artery embolization for osteoarthritis knee pain; hemorrhoidal embolization with HydroPearl microspheres; bariatric arterial embolization; prostatic arterial embolization for BPH) may be denied as not medically necessary.
- Genicular artery embolization for osteoarthritis knee pain
- Hemorrhoidal embolization (HydroPearl microspheres)
- Bariatric arterial embolization to treat obesity
- Prostatic arterial embolization for benign prostatic hyperplasia
Insufficient evidence may trigger noncoverage
Procedures or indications supported only by insufficient evidence (for example, preventive collateral arteries embolization to reduce type II endoleaks, locoregional embolization for metastatic pancreatic cancer, or other emerging/novel embolizations) may be considered investigational and at risk for noncoverage.
- Preventive collateral arteries embolization before EVAR to reduce type II endoleak
- Locoregional embolization for metastatic pancreatic cancer outside clinical trials
- Other emerging embolization applications described as having insufficient evidence
Member financial liability risk
Services determined to be not medically necessary or non‑covered benefits may be denied and could result in member financial liability unless the member has been informed and agreed in writing in advance.
- Providers may not charge the member for non‑covered services unless the member provided written informed agreement
- Refer to participation agreement provisions for billing and member notification
Background and Rationale
Vascular embolization comprises endovascular procedures that occlude vessels to stop arterial bleeding, reduce blood flow to tumors or malformations, or redirect circulation without open surgery. The policy notes common, accepted uses such as embolization for active GI bleeding, renal angiomyolipoma with hemorrhage, splenic artery embolization, tumor devascularization, and portal vein embolization to induce hypertrophy of the future liver remnant prior to resection. It also emphasizes that certain organ‑specific embolizations (notably hepatic and uterine fibroid embolization) are managed under separate prior authorization policies and that clinical selection depends on indication severity and available evidence.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.